Immuron (ASX:IMC) said fiscal 2025 sales are "on track" to exceed AU$7 million, up from AU$4.9 million a year earlier, according to a May 30 filing with the Australian bourse.
All of the US armed services participants in the field study for Travelan, the company's therapy candidate for traveler's diarrhea, have been deployed, the filing said.
The biopharmaceutical firm expects the final visit of the last patient in July, with results slated for release in October, the filing added.
The company also expects an investigational new drug submission for IMM-529, a drug candidate for colon infection, to the US Food and Drug Administration in August.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.